Company intelligence / Profile preview
Saros Therapeutics
- Ownership
- Private
- Employees
- ~4
- Development stage
- Preclinical
Overview
The company is working to complete IND filing and begin first-in-human trials in solid tumors. Multiple pre-clinical models in mice, rabbits, and human cell lines support the efficacy and safety of their first agent.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Nanoparticle immunotherapySTING agonists
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Saros Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Saros Therapeutics.